Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.

Paola Leone  
CNS Gene Therapy Center Department of Neurosurgery Thomas Jefferson University Philadelphia PA 19107 USA,  
Paola.Leone@mail.tju.edu

Christopher G Janson  
Cooper University Hospital, Departments of Neurology and Molecular Genetics Camden, NJ USA

Scott J McPhee

Matthew J During  
Ohio State University Comprehensive Cancer Center, Comprehensive Cancer Center Columbus, OH USA

Let us know how access to this document benefits you

Follow this and additional works at: https://jdc.jefferson.edu/neurosurgeryfp

Part of the Medical Neurobiology Commons, Neurology Commons, and the Surgery Commons

Recommended Citation  
Leone, Paola; Janson, Christopher G; McPhee, Scott J; and During, Matthew J, "Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease." (1999). Department of Neurosurgery Faculty Papers. Paper 8.  
https://jdc.jefferson.edu/neurosurgeryfp/8

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease
Paola Leone, Christopher G Janson, Scott J McPhee & Matthew J During

Address
CNS Gene Therapy Center
Department of Neurosurgery
Thomas Jefferson University
Philadelphia
PA 19107
USA
Email: Paola.Leone@mail.tju.edu

© PharmaPress Ltd ISSN 1466-8431

The neurogenetic prototypic disease on which we chose to test our gene therapy strategy is Canavan disease (CD). CD is an autosomal recessive leukodystrophy associated with spongiform degeneration of the brain. At present the disease is uniformly fatal in affected probands, CD is characterized by mutations in the aspartoacylase (ASPA) gene, resulting in loss of enzyme activity. In this review, recent evidence is summarized on the etiology and possible treatments for CD. In particular, we discuss two gene delivery systems representing recent advances in both viral and liposome technology: a novel cationic liposome-polymer-DNA (LPD) complex, DCCChol/DOPE-protamine, as well as recombinant adeno-associated virus (AAV) vectors.

Introduction and background
In our recent era of molecular medicine, physicians are compelled to think in terms of the genetic basis of disease, the expectation being that pathology can be ultimately explained as a collection of (genetically influenced) biochemical defects. CD, or N-acetyl aspartic acylase deficiency, is a fatal childhood leukodystrophy that is typified by lack of hydrolysis of N-acetyl aspartate (NAA), leading to a local build-up of NAA in the brain as well as a NAA acidemia and aciduria. It was first presented in a case report by Myrtelle Canavan in 1931 as a variant of Schilder’s panencephalitis [1], rather than CD and it was left to subsequent investigators to elucidate the distinctive pathology. A similar morphological change can occur after exposure to certain toxins (eg, triethyl tin, cuprizone, iproniazid). The first ultrastructural study was published by Adachi in 1966, and demonstrated large spaces within the myelin sheaths, as well as swollen astrocytes. The nuclei and cell bodies of neurons are generally intact without evidence of abnormalities. Vacuolated oligodendrocytes are seen occasionally, but most oligodendroglia are normal even in areas of expanded extracellular fluid mainly within the myelin lamellae and astrocytic processes [10]. Elongated mitochondria are typically observed in the astrocytes. The nuclei and cell bodies of neurons are generally intact without evidence of abnormalities [9]. Vacuolated oligodendrocytes are seen occasionally, but most oligodendrogria are normal even in areas of expanded extracellular space and disintegrating myelin sheaths. In the cortex, the ‘sponginess’ was found in one study to correspond to swollen astrocytes, whereas in white matter the vacuoles were formed by the intramyelinic extracellular fluid (ECF) [11]. In general the entire central nervous system (CNS) is affected, with vacuolization of white matter most evident in the cerebellum and brainstem [12].

The relationship of NAA and ASPA to the disease pathology
It is interesting that NAA is strictly compartmentalized within the brain. NAA is synthesized only in the CNS, and more specifically only within the mitochondria of neurons...
It is found in high concentrations within neurons (5 to 10 mM) and it has long been considered a neural-specific marker. On the other hand, ASPA has a wide tissue distribution and it has been isolated from human kidney, adrenal glands, lung, liver and skin. Within the brain, ASPA is predominantly localized to the white matter, where it is found in highest concentration among the axons and myelin. It has been reported that ASPA in gray matter and blood components is undetectable. This fact is significant, because bone marrow transplant (BMT) has been suggested as a possible ameliorative measure to lower NAA in CD, and a patient recently received a BMT in the hope of lowering systemic NAA [Krivit W, personal communication]. BMT has been used in a number of other CNS leukodystrophies, but its relevance in CD is unknown.

Interstitial levels of both NAA and NAAG (N-acetyl-aspartyl-glutamate, a biosynthetic product of NAA) are elevated in CD. Neurons have a severalfold increased level of NAA over white matter and yet the gray matter is spared significant pathological change in CD, which argues against a directly toxic role of NAA in the pathogenesis. However, one hypothesis has been that high levels of NAA may be toxic when applied to glial cells, yet neuronal cells are spared. Studies on NAA and NAAG, demonstrate limited binding at NMDA receptors and suggest the possibility of toxic effects on neurons in vitro [19]; relatively low levels (approximately 1 mM) of either NAA or NAAG are not neurotoxic when applied to neuronally-enriched cell culture, but higher levels of NAA (approximately 3 to 10 mM) can elevate intracellular calcium up to 3-fold. Some glial cells are known to be susceptible to glutamate excitotoxicity, but the fact that ultrastructural studies have shown limited oligodendrocyte cell body involvement in CD argues against a simple cytotoxic hypothesis of NAA or NAAG for those cells.

The normal function of NAA has been debated for some time. It has been suggested that a main role is as an acetyl donor in lipogenesis. The acetyl group of NAA is incorporated into a variety of lipids in brain and liver; it is converted to acetate and acetyl-CoA in both tissues. Therefore one hypothesis is that NAA functions as a storage form of acetate and for acetyl-CoA production. The implication for CD is that a decrease in NAA and a continuous NAA efflux into the ECF. This model predicts a mild aspartate deficit in CD caused by a failure to degrade NAA. Baslow has described a ‘near-field’ and a ‘far-field’ cycle for NAA. The purpose of the far-field cycle would be to transport aspartate from the periphery, perhaps using erythrocytes (which concentrate aspartate) as a vehicle. The lack of CD pathology in vivo is attributed to the protective effect of the maternal circulation, which supplies aspartate to the fetus. If hypo-aspartia indeed constitutes an important aspect of the pathology, this model predicts that infusion of aspartate into ASPA-deficient animals or humans might be beneficial if higher, but nontoxic levels within the CNS are maintained. It has been suggested by a number of investigators that a state of hypo-aspartia induced by failure of the normal NAA cycle might lead to a decreased generation of oxaloacetate (the rate-limiting substrate for the tricarboxylic acid cycle) through a decrease in transamination reactions, which could in turn disrupt cellular metabolism; research groups are currently collaborating with Keith Hyland to quantify (using HPLC techniques) cerebroventricular metabolites that may support or disprove this hypothesis.

The idea of osmolar disequilibrium as an underlying cause of edema in CD is not new. Some researchers have looked specifically at Na+/K transporters, given a similar spongiform pathology that occurs as a result of treatment in experimental animals with ouabain, which blocks the Na+/K transporter and causes pathological swelling of astrocytes and presynaptic axon terminals. Yet there appears to be no pathology specific to these transporters. In spongy degeneration the synapses display a normal ATPase activity and the axon terminals are unchanged; however, the mitochondrial ATPase activity is somewhat decreased, perhaps a marker of overstrained mitochondria and a possible cause of the typical astrocytic swelling. The abnormal mitochondrial ultrastructure in CD tends to suggest a role for metabolic or energetic causes in the pathogenesis of CD, and it is possible that water imbalance acts to exacerbate co-existing metabolic or energetic problems.

In summary, there are several possible theories of the normal role of NAA (lipid biosynthesis precursor, TCA intermediate and osmolyte) and its role in the pathology of CD when ASPA is deficient (cytotoxic, metabolic and osmotic). The relative importance of each of these factors, and how they may work together, has yet to be determined.
Prenatal diagnosis
CD is associated with a marked increase in NAA levels in cerebral spinal fluid (CSF), plasma and urine. This biological marker became the primary method of diagnosis following identification of ASPA deficiency in the late 1980s [5•]. Prior to that time, surgical brain biopsy in conjunction with computed tomography (CT) was the best method for diagnosis. Prenatal genetic counseling and testing is now available for CD, and is recommended for Ashkenazi Jewish descendents (who have a carrier frequency of approximately 1 in 40) and all other patients in a high-risk group. Polymerase chain reaction (PCR)-based genetic testing is available for well-characterized mutations.

Canavan disease and symptomatic therapies
The severity of CD symptoms varies significantly on a case by case basis. The clinical course of the disease is relentlessly progressive, although the rate of deterioration is variable. At present there is no treatment of proven efficacy, although gene therapy seems to be the most promising approach, particularly as vector design and delivery improves (Figure 1). Current management is based on a combination of physiotherapy procedures and supportive strategies such as dietary modifications (eg, ketogenic diet), nutritional supplements (eg, carnitine, calcium acetate) and palliative drug regimens such as anti-epileptics, anxiolytics and diuretics.

Calcium acetate (15 to 30 mg/kg per day) and acetazolamide (5 to 7 mg/kg per day) administration may be indicated in CD. Controlled studies have not yet been performed, but there is anecdotal evidence suggesting that combination of these two drugs is associated with improvements in neurological function in children with CD (Kolodny E, personal communication). The calcium acetate (PhosLo) was originally given to CD patients to control hyperphosphatemia, and was incidentally found to improve mental function, possibly through increased lipid synthesis; the diuretic is intended to decrease ECF in the brain.

Another possible therapeutic approach might include the use of the recombinant ASPA enzyme delivered directly into the brain of children with CD. This approach has not been developed sufficiently to demonstrate all the risks (in addition to surgery), but based on the outcome of an Israeli trial on brain delivery of hexaminadase A to children with Tay Sach’s disease, such an approach is unlikely to afford adequate or long-term benefits [23].

Canavan disease and gene therapy
Considered together, the leukodystrophies are attractive candidates for replacement gene therapy, considering the catastrophic effects of the diseases, the absence of other effective treatments and the fact that a single gene etiology has been identified for a number of these disorders. CD as a target is particularly attractive because the pathology is restricted to the brain rather than being multisystemic, and the effect of gene transfer (ASPA delivery) can be followed non-invasively using 1H-NMR of brain NAA levels.

There are a number of obstacles to effective AAV-mediated ASPA gene therapy, among them the problem of targeting all the affected cells and achieving sufficiently long-term levels of gene expression. On the bright side, it is possible that only a small fraction of transduced cells might correct the abnormal ASPA function in CD patients. Studies of heterozygote carriers of ASPA mutation alleles demonstrated that ASPA activity in fibroblasts might be only 40% that of non-carriers, yet heterozygotes have no phenotype [24]. Therefore even modest gains in enzyme activity may be sufficient to lower NAA and to have an effect on the disease course. In addition, there is a late-onset variant of CD (onset of severe symptoms after the age of 5 years) with less elevation of NAA in the brain, which is hypothesized to have a milder ASPA defect than the early-onset CD patients. In two children with this juvenile form of the disease, urine NAA levels were elevated, but CNS levels of NAA were initially normal as measured by 1H-NMR [25].

Figure 1. The first four children with Canavan disease enrolled in the gene therapy phase I trial (post-gene delivery).
In these two patients, activity of ASPA in skin fibroblasts was only 4 to 5% of wild-type, yet the children had minimal leukodystrophy at the ages of 2 and 4 years. It is possible that this milder phenotype, in which brain NAA elevation is less pronounced and symptoms are delayed, may be reproduced by overexpressing ASPA in the brain.

Despite the hurdles that the brain poses for gene therapy, significant advances have been made in two delivery systems (liposomal and viral) for gene transfer to the CNS. The first is a second generation, liposome-based delivery system based on the DC-Chol/DOPE together with protamine as a DNA-condensing agent. The most recent is recombinant AAV vector: a defective, human non-pathogenic parvovirus. It has been shown that AAV can safely and effectively transduce mammalian neurons and glia, and in a rodent model of Parkinson’s disease, long-term phenotypic correction has been shown [24]. Furthermore, as AAV is extremely small (only 20 nm), using strategies to modify the blood-brain barrier it may more readily cross into and through the brain parenchyma.

Over the past 5 years, investigators have generated sufficient safety data in rats and primates to achieve approval for two clinical phase I studies (University of Auckland, New Zealand 1996, Yale University/Thomas Jefferson University/Advanced Therapies Inc, US 1998) for ASPA gene therapy in children affected by CD (Figure 2); the development of a homologous knockout mouse model of CD is still in progress, and therefore no efficacy data could be generated at the time that the clinical studies were first approved. An ASPA-expressing plasmid with the transcription unit flanked by AAV-inverted terminal repeats (ITRs) was constructed and tested in vitro for ASPA expression, and high levels of enzyme activity were obtained; this plasmid was then used in a non-viral vector complex for animal expression and toxicity studies. ASPA transgene expression was observed at the level of mRNA using reverse transcriptase (RT)-PCR with primers specific to the vector-encoded ASPA. There is still no monoclonal antibody to ASPA, and therefore detection at the protein level was not possible, except for fusion gene constructs.

As a delivery method, a novel liposome-encapsulated, condensed plasmid DNA (LPD) was chosen [26]; the expression plasmid consisted of the early cytomegalovirus (CMV) promoter, the human aspartoacylase (ASPA) full-length cDNA and a SV40 polyA flanked by AAV 145 base pair ITRs. The LPD complex was designed to be delivered into the cerebral ventricles, the rationale being that a large surface area of brain tissue could be transduced if the vector penetrated the ependymal cells. Results in animals showed expression in ependyma (periventricular cells) with some limited expression extending into parenchyma. The liposome used in the gene therapy trials was originally synthesized in January 1992 at the University of Pittsburgh and was the same batch used for other gene therapy phase I trials [27,28]. Poly-L-lysine was used as a cationic polymer during the first gene therapy trial in New Zealand in two children, and protamine in 14 children during the phase I trial in the USA.

This intervention represented the first human gene therapy trial for a neurodegenerative disease, and an important ‘proof-of-principle’ study of an otherwise fatal disease. Initial results appear promising, bearing in mind that the endpoints of phase I studies are those of safety and tolerability. Following the demonstration of safety, efforts are being directed towards further defining the efficacy of this treatment, using a number of clinical outcome measures: CSF analysis, MRI (myelin quantification), H-NMR spectroscopy (NAA quantification), evoked potentials (auditory, visual, somatosensory and brainstem), neurological evaluation, and parental reports with
videotapes. Preliminary (unpublished) data using AAV-ITR-based condensed plasmid vectors suggest that non-viral, in vivo gene therapy of CD is safe and may be associated with some biochemical, radiological and clinical benefit. Currently our efforts are focused on the improvement and testing of high-titer, ultrapure ASPA-AAV viral vectors for use in future clinical trials. The original phase I safety trial is ongoing in terms of data collection, but has paused in terms of vector administration, in order to accommodate vector improvements and testing; it is hoped that new AAV vectors, driven by a variety of brain-specific promoters, will afford greater long-term expression of the deficient enzyme.

Conclusion
CD is a noteworthy and tragic disease, yet the importance of this study extends well beyond CD. Progress toward safe and effective gene therapy will help in the development of better treatments for a host of other neurological disorders, whether lysosomal, peroxisomal, metabolic or multifactorial. This century has seen ground-breaking medical discoveries, which have uncovered the biochemical pathways as well as the genetic identity underlying many diseases; the crucial steps involved in designing an effective gene-based therapy include determining the function of the key gene products associated with a given disease, identifying and characterizing the relevant genes, and finally manipulating them at will with the aid of new generation delivery vectors. This is the ultimate goal and challenge of gene therapy: to make biochemistry the servant of our genetic interventions.

References

- of outstanding interest
- of special interest


